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Abstract
To determine if patients with myasthenia gravis (MG) have antibodies to agrin, a proteoglycan released by motor neurons
and is critical for neuromuscular junction (NMJ) formation, we collected serum samples from 93 patients with MG with
known status of antibodies to acetylcholine receptor (AChR), muscle specific kinase (MuSK) and lipoprotein-related 4 (LRP4)
and samples from control subjects (healthy individuals and individuals with other diseases). Sera were assayed for
antibodies to agrin. We found antibodies to agrin in 7 serum samples of MG patients. None of the 25 healthy controls and
none of the 55 control neurological patients had agrin antibodies. Two of the four triple negative MG patients (i.e., no
detectable AChR, MuSK or LRP4 antibodies, AChR-/MuSK-/LRP4-) had antibodies against agrin. In addition, agrin antibodies
were detected in 5 out of 83 AChR+/MuSK-/LRP4- patients but were not found in the 6 patients with MuSK antibodies
(AChR-/MuSK+/LRP4-). Sera from MG patients with agrin antibodies were able to recognize recombinant agrin in
conditioned media and in transfected HEK293 cells. These sera also inhibited the agrin-induced MuSK phosphorylation and
AChR clustering in muscle cells. Together, these observations indicate that agrin is another autoantigen in patients with MG
and agrin autoantibodies may be pathogenic through inhibition of agrin/LRP4/MuSK signaling at the NMJ.
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Introduction
Autoimmune MG is the most common disorder of NMJ,
affecting nearly 20 per 100,000 people in various populations [1–
5]. MG patients show characteristic fatiguing weakness of
voluntary ocular, bulbar and limb muscles, dysarthria, dysphagia
and in severe cases death from difficulty with breathing. The
symptoms and pathology of MG are known to be due to an
antibody-mediated, autoimmune attack directed against molecules
at the NMJ. Autoantibodies against AChR can be detected in the
circulation of ,80–90% of MG patients [6,7]. Evidence from
classic experiments indicates the anti-AChR antibodies are
pathogenic [8–11].
However, AChR antibodies cannot be detected in ,10–20% of
generalized MG patients. Recent studies shed light on under-
standing the pathology in these ‘‘seronegative’’ MG. Approxi-
mately 40–70% of the seronegative patients have antibodies
against MuSK [4,5,12–15]. Our group and others also reported
that 2–50% of AChR and MuSK double seronegative patients
have anti-LRP4 antibodies [16–19].
However, in at least 2–5% of MG patients identifiable
antibodies to a known autoantigen have not been detected. The
NMJ is a cholinergic synapse that rapidly conveys signals from
motoneurons to muscle cells [20–26]. Previous studies suggest a
critical role of the agrin/LRP4/MuSK pathway in formation of
the NMJ. Neuronal agrin is a large extracellular matrix protein
utilized by motoneurons to induce AChR clustering and
postjunctional differentiation [27–32]. Agrin binds to LRP4 to
form a tetrameric complex, which interacts with and activates
MuSK to initiate downstream signaling cascades mediating AChR
clustering [33,34]. Ablation of the genes encoding for agrin,
MuSK or LRP4 prevents NMJ formation [35–41]. We posit that
agrin may be a potential autoantigen for its function at the NMJ
and spatial proximity with AChR, MuSK and LRP4.
Here we show that approximately 50% of known triple
seronegative MG patients (i.e., no detectable AChR, MuSK or
LRP4 antibodies, AChR-/MuSK-/LRP4-) have serum antibodies
against agrin, representing approximately 2–3% of all MG
patients in our study. The agrin autoantibodies recognized agrin
protein expressed in transfected HEK293 cells and inhibited agrin-
induced AChR clustering in cultured myotubes. Our results
indicate the potential involvement of agrin antibody in the
pathogenesis of AChR/MuSK/LRP4-seronegative MG, thus
defining one novel immunological form of the disease. Measure-
ment of agrin antibodies would also substantially aid diagnosis and
PLOS ONE | www.plosone.org 1 March 2014 | Volume 9 | Issue 3 | e91816
clinical management. In addition, agrin antibodies are also found
in the serum of patients with antibodies to other components of the
NMJ such as AChR, although not to date in our studies in those
with MuSK antibodies. Studies of those patients might contribute
to understanding the pathogenic mechanisms of the disease.
Materials and Methods
Ethics statement
Serum samples from Wayne State University were all archival
and had been previously collected as part of prior Wayne State
University IRB approved research studies or as additional serum
obtained at the time of diagnostic studies, with informed consent
for all samples. All samples were anonymized.
Patient sera
Serum of 93 patients with MG had previously been tested for
anti-AChR and anti-MuSK antibodies or tested for these
antibodies for this study. Additionally we tested serum of 6
patients with MG in whom we had no data on antibody status to
AChR, MuSK but were known to be negative for LRP4
antibodies. All of these were negative for agrin but since we have
no data on the antibody status of these sera, they have not been
included in the statistical analysis. Patients and healthy volunteers
gave their written informed consent. Serum samples were assayed
for AChR binding antibody at ARUP Laboratories (Salt Lake
City, UT; positive $0.5 nM/L), at the Mayo Clinic (Rochester,
MN; positive .0.02 nM/L) or at Athena laboratories ($0.5 nM/
L). Anti-MuSK was either assayed by Dr. Angela Vincent as part
of a multi-institutional study of serum from MG patients (positives
as defined previously [12]) or by a commercial laboratory
(Athena). LRP4 antibodies were examined in our previous report
[16]. Seropositive MG was defined as AChR, MuSK and/or
LRP4 antibodies positive. Normal control sera were obtained from
age and gender-matched volunteers serving as controls of other
studies of MG. In addition, sera from patients with the following
diseases were examined: amyotrophic lateral sclerosis (ALS)
(n = 9); chronic inflammatory demyelinating polyneuropathy
(CIDP) (n = 4); primary CNS Sjogrens syndrome (n= 2); Guil-
lain-Barre syndrome (GBS)/acute inflammatory demyelinating
polyneuropathy/(AIDP) (n = 6); acute motor axonal neuropathy
(AMAN) (n= 1); GBS with concomitant Isaac’s syndrome (n = 1);
CNS Lyme disease (n = 1); multiple sclerosis (MS) (n = 20);
paraneoplastic neuropathies (n = 2); polymyositis in a patient with
primary Sjogrens syndrome (n= 1); polychondritis with CNS
vasculitis (n = 1); neuromyelitis optica spectrum disorder
(NMOSD) (n= 1); inflammatory myelopathies (not transverse
myelitis or NMO)(n = 3); peripheral neuropathy of unknown
etiology (n = 1); and neuroscarcoisis (n = 1). Overall, we tested sera
from 93 immunologically-characterized MG patients, including
AChR+/MuSK-/LRP4- (n = 83), AChR-/MuSK+/LRP4- (n = 6)
and AChR-/MuSK-/LRP4- (n = 4). There were also 4 who were
previously shown to be LRP4- but of unknown status re: AChR
and MuSK antibody (negative for agrin as noted in Results, these
were not among the 93 in the final data analysis) and sera from
normals (n = 25) and other disease controls (n = 55) as indicated
above were assayed for antibodies to agrin.
Recombinant protein production and purification
pFlag-agrin construct was described previously [42]. Of note,
this construct contains 6XHis tag between Flag-tag and agrin
coding sequence, enabling metal affinity chromatography for
recombinant agrin protein. HEK293 cells were transfected with
pFlag-agrin and 24 hr later, cells were switched to Dulbecco’s
Modified Eagle Medium supplemented with reduced concentra-
tion (0.5%) of fetal bovine serum. Conditioned media containing
secreted agrin proteins were harvested 24 hr later and were
purified by affinity chromatography using TALON Resins (BD
Biosciences). Expression and purification of agrin proteins were
verified by Western blot with anti-Flag antibody (Sigma).
ELISA detection of antibodies to agrin
Maxi-Sorp Immuno 96-well Plates (Nunc) were coated with
50 ml of 1 mg/ml agrin in the coating buffer containing 50 mM
carbonate (pH 9.6) at 40C overnight, washed six times with TBST
(0.1% Tween 20 in 50 mM Tris, 150 mM NaCl, pH 7.6) and
incubated with the blocking buffer containing 5% nonfat milk in
TBST to block non-specific binding. Sera were diluted 1:10 in the
blocking buffer (100 ml per well) and incubated for 1 hr at 370C.
After six washes with TBST, the wells were incubated with
alkaline phosphatase (AP)-goat anti-human IgG+IgM+IgA as the
secondary antibody (Abcam), diluted 1:30,000 in TBST, at 37uC
for 1 hr. Activity of immobilized AP was measured by optical
density (OD) assay (at 405 nm) following incubation in the
substrate buffer containing 0.5 mM MgCl2, 3 mg/ml p-nitrophe-
nyl phosphate (pNPP) and 1 M diethanolamine (DEA), at room
temperature for 30 min. Each sample was assayed in duplicate
and repeated more than three times. Nonspecific signal was
determined by OD reading of wells coated with the coating buffer
alone followed by incubation of secondary antibody and substrate.
Cut-off value was set as mean +3 standard deviation (SD) of
control normal human serum, representing confidence of 99.7%.
Immunoprecipitation of agrin by serum samples with
agrin autoantibodies
Conditioned media containing Flag-agrin were incubated with
10 ml of sera (sera 1–21, 1–106, 2–17, 2–27 and normal human
serum control) at 4uC overnight with agitation, followed by 2 hr
incubation with 50 ml Protein-G beads at 4uC. Bead-immobilized
proteins were subjected to SDS-PAGE and western blotting with
anti-Flag antibody.
Immunostaining of agrin-transfected HEK293 cells by
serum samples
HEK293 cells were transfected with pFlag-agrin and 72 hr
later, cells were washed briefly with PBS and fixed in 4%
paraformaldehyde. After permeabilization with 0.5% Triton X-
100 in PBS for 5 min, cells were blocked with blocking buffer
containing 10% normal goat serum and 1% BSA in PBS. MG
patient and normal human control serum samples were diluted
1:10 in blocking buffer containing rabbit anti-Flag antibody (1:500
dilution) and incubated with cells at 4uC overnight. After wash,
FITC labeled goat anti-human IgG secondary antibody (Southern
Biotech) and Alexa 594 labeled donkey anti-rabbit secondary
antibody (Invitrogen) were added and incubated for 1 hr. After
wash, cells were mounted and viewed under a Zeiss epifluoresence
microscope. At least 5 views per dish and at least 2 dishes were
scored in two independent experiments. All samples were
examined blindly without previous information of the diagnosis.
Effects of agrin positive sera on agrin-induced MuSK
phosphorylation and AChR clustering
Agrin-induced MuSK phosphorylation and AChR clustering
were assayed as previously described [33,43,44]. Briefly, C2C12
myotubes were treated with neural agrin (10 ng/ml) [33] together
with agrin positive sera (1:100 dilution) (sera 1–21, 1–106, 2–17,
2–27) or normal human control serum for 30 min. After brief
Agrin Antibodies and Myasthenia Gravis
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wash, cells were lyzed in RIPA buffer and incubated with anti-
MuSK antibody at 4uC overnight with agitation, followed by 2 hr
incubation with 50 ml Protein-G beads at 4uC. Bead-immobilized
proteins were subjected to SDS-PAGE and western blotting with
anti-phospho-tyrosine antibody 4G10 (Millipore). For AChR
clustering assay, myotubes were treated with neural agrin
(10 ng/ml) together with agrin positive sera (1:100 dilution) (sera
1–21, 1–106, 2–17, 2–27) or normal human control serum for
16 hr, then fixed in 4% paraformaldehyde, and incubated with
50 nM rhodamine-conjugated-bungarotoxin (R-BTX) (Invitrogen)
to label AChR clusters. Myotubes were viewed under a Zeiss
epifluoresence microscope and AChR clusters with diameters or a
longer axis $4 mm were scored. At least 10 views per dish and at
least 2 dishes were scored in each of three independent
experiments.
Statistical Analysis
For ELISA examination of control and MG patient sera, all
samples were tested in triplicate in three independent experiments.
The cut-off value was set as mean +3 SD of normal human serum
samples to represent 99.7% confidence. For AChR clustering
assay, data of multiple groups was analyzed by ANOVA, followed
by a student-New-man-Keuls test. Differences were considered
significant at p,0.05.
Results
Detection of agrin autoantibodies in sera of MG patients
To determine whether sera of MG patients have agrin
autoantibodies as well as to characterize those sera with regard
to antibodies to other known autoantigens at the NMJ, we
generated Flag/His-tagged rat agrin (His1137 to Pro1940). The
purified protein resolved around 120 kDa on SDS-PAGE.
Moreover, it could be detected by a commercial antibody against
the Flag epitope (data not shown). The agrin protein was used in
ELISA assays for autoantibodies in sera from MG patients as well
as various groups of control individuals. With the mean plus 3 SD
of normal sera as cut-off, none of the serum samples from normal
individuals were positive for agrin antibodies. No positive sera
were detected from patients with non-MG neurological disorders
as defined in methods (Fig. 1). Of 93 MG patients, 7 were positive
for agrin autoantibodies: 5 were AChR+, but MuSK- and LRP4-
patients and 2 were from patients who were ‘triple seronegative’
(no AChR, MuSK or LRP4 antibodies) (Fig. 2). As noted earlier,
there were sera from 6 patients with MG who were known to be
negative for LRP4 antibodies but had not been tested for AChR
and MuSK antibodies and they were all negative for agrin
antibodies (data not shown in Figs. 1 or 2).
To confirm that the target antigen of these sera was agrin,
rather than any contaminant in the agrin preparation, we
examined whether the agrin positive sera could recognize agrin
in soluble form. Four agrin+ sera were incubated with Flag-agrin
conditioned media. The immunocomplex was purified by protein
G immobilized on beads, resolved by SDS-PAGE and subjected to
western blot analysis with anti-Flag antibody. As expected, agrin
was not detectable in the immunocomplex by normal human
serum. However, Flag-tagged agrin was detected in the precipi-
tates by 4 agrin positive sera, indicating that agrin autoantibodies
were able to recognize agrin protein in solution from transfected
cells (Fig. 3).
To further confirm that the sera are able to recognize agrin in
natural condition, we examined whether the agrin positive sera
Figure 1. Detection of agrin autoantibodies in MG patient
samples. Optical density readings of normal human serum were 0.18
6 0.16 (mean6 SD, n = 25). The green dotted line was set as mean + 3
SD to indicate the cut-off. The red dots indicate positive for agrin
antibodies. NHS, normal human serum; OND, other neurological
diseases, n = 55; MG, myasthenia gravis, n = 93.
doi:10.1371/journal.pone.0091816.g001
Figure 2. Distribution of agrin autoantibodies among MG
patients. Of 93 MG samples previously analyzed for antibody to AChR,
MuSK and LRP4, 83 were AChR+/MuSK-/LRP4-; 4 were triple seroneg-
ative (AChR-/MuSK-/LRP4-) and 6 were AChR-/MuSK+/LRP4-. The cut-off,
indicated by the green line, was set as mean + 3 SD. The red dots
indicate positive for agrin antibodies.
doi:10.1371/journal.pone.0091816.g002
Figure 3. Recognition of agrin protein by serum samples with
agrin autoantibodies. Conditioned media from Flag-agrin-transfect-
ed HEK293 cells were incubated with serum samples with agrin
antibodies or normal human serum samples. Immunocomplex and
conditioned media (to indicate equal amounts of input) were subjected
to Western blotting with anti-Flag antibody.
doi:10.1371/journal.pone.0091816.g003
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could detect agrin in transfected cells. One agrin positive serum
(2–17) was used to stain HEK293 cells transfected with Flag-agrin
construct. As expected, agrin positive serum was able to detect
transfected agrin in HEK293 cells, co-staining with anti-Flag
antibody. However, Flag-tagged agrin was not detected by normal
human serum, indicating that agrin autoantibodies were able to
recognize agrin protein in transfected cells (Fig. 4).
Alteration of agrin-induced MuSK phosphorylation and
AChR clustering by agrin autoantibodies
Agrin induces Tyrosine phosphorylation of MuSK, which is
critical for downstream cascades activation and agrin-induced
AChR clustering [45]. We speculated the autoantibodies may
change agrin-induced MuSK phosphorylation and thus AChR
clustering. To test this hypothesis, C2C12 myotubes were treated
with neural agrin alone or together with control or agrin+ sera,
and examined for MuSK phosphorylation and AChR clusters. As
shown in Fig. 5A, neural agrin induced MuSK phosphorylation in
myotubes without serum treatment or treated with normal human
serum. However, the phosphorylation was decreased in anti-agrin
sera treated myotubes, especially 1–21 and 2–17 samples,
indicating the blocking effect of the autoantibodies on agrin
signaling. In AChR clustering assay (Figs 5B and 5C), agrin-
induced AChR clusters in myotubes were not altered by normal
human sera, but were inhibited by all agrin positive sera. These
results suggest that agrin autoantibodies may have pathogenic role
through its inhibition on AChR clustering induced by agrin.
Discussion
About 80–90% of MG patients have detectable serum
antibodies against AChRs with 40–70% of the remaining patients
being positive for anti-MuSK antibodies and 2–50% for anti-
LRP4 antibodies [12,16–18,46]. This would leave approximately
2–5% of the MG patients triple seronegative, i.e., without
detectable antibodies against any known autoantigen (AChR,
MuSK or LRP4) at the NMJ. This study presents evidence that
Figure 4. Recognition of agrin from transfected HEK293 cells by agrin+ serum. Agrin positive serum 2–17 stained positively with HEK293
cells transfected with Flag-agrin construct, co-staining with anti-Flag antibody. Normal human serum cannot recognize agrin-transfected cells.
doi:10.1371/journal.pone.0091816.g004
Figure 5. Serum samples with agrin antibodies inhibit agrin-induced MuSK phosphorylation and AChR clustering in myotubes. A,
Anti-agrin autoantibodies inhibit agrin-induced MuSK phosphorylation. C2C12 myotubes were incubated without or with agrin and serum samples.
Endogenous MuSK was precipitated by MuSK antibody and its phosphorylation was examined by 4G10 antibody. NS, no serum. B, Anti-agrin
autoantibodies inhibit agrin-induced AChR clustering. Representative images. C, Quantitative data of basal (W/O agrin, green) and induced (W/agrin,
red) AChR clusters. Data shown were mean 6 SEM. *, p , 0.05, compared with control.
doi:10.1371/journal.pone.0091816.g005
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anti-agrin autoantibodies exist in sera of the triple seronegative
MG patients, as well as in patients with AChR antibodies. In our
cohort of 93 serologicallly characterized patients, 7 were found
positive for anti-agrin antibodies, accounting for about 7–8% of all
MG patients. The presence of agrin antibodies in 2 out of 4 ‘triple
seronegative’ patients with MG suggests that agrin may be a novel
antigen in some triple seronegative MG patients. It is worth noting
that we found no agrin antibody in any of our patients who had
MuSK antibodies. Since none of the 93 patients tested for agrin
antibodies in this study were positive for LRP4 antibody as tested
in our previous paper [16], we do not know if some LRP4+
patients will be found to have agrin antibodies in future studies.
During the preparation of this study, a group from the United
Kingdom reported the detection of agrin autoantibody in
seronegative MG patients [47] using a cell-based assay. They
found that in triple seronegative MG patients, 15% were anti-
agrin positive. Also they showed high percentage of overlapping
between AChR+ and agrin+ patients (13 AChR+ in total 24
agrin+ patients). Although detailed methodology was not included,
the results from the report support what we observed in current
study. Due to the time consuming nature of cell-based methods,
our ELISA-based assay reported here would provide a convenient
yet reliable clinical diagnostic test with quantitative value.
Pathogenic mechanisms of AChR antibodies have been well
studied. In rabbit, mouse, and rat models of experimental
autoimmune myasthenia gravis (EAMG), anti-AChR antibodies
block the activity of the AChR [48,49] and may accelerate the
internalization and degradation of AChRs [50]. In addition, the
autoantibodies may fix complement, leading to complement
activation causing damage and simplification of the postsynaptic
membrane of the NMJ [10,51–54]. The AChR deficiency
decreases the amplitude of miniature end-plate potentials (mEPPs)
and hence that of end-plate potentials (EPPs), which consequently
reduces the safety margin of neuromuscular transmission [10,11].
On the other hand, MuSK antibodies seem to inhibit the activity
of MuSK, leading to attenuation of agrin-induced AChR
clustering thus reducing AChR levels at the junctional folds [55–
59]. In addition, NMJs and AChR scaffolds are disrupted in
MuSK antibody induced EAMG. However MuSK antibodies in
MG patients are predominantly of the IgG4 subclass [60,61]
which does not bind and activate complement. Thus, it seems that
MuSK antibody-associated MG may have different etiological and
pathological mechanisms from those of the AChR antibody
associated MG. This concept is also supported by the observation
that MG patients with MuSK antibodies patients do not appear to
have thymic hyperplasia or thymoma [62–66]. The pathogenic
role of LRP4 autoantibodies has been presented in the EAMG
recently by our lab [67].
Whether and how agrin autoantibodies are pathogenic requires
further study. We have demonstrated that some agrin+ sera were
able to inhibit agrin-induced AChR clustering which provides one
possible pathologic role of these antibodies in vivo. It is of note that
agrin protein has multiple isoforms and can be secreted by muscle
and motor neuron (muscle and neural agrin, respectively) [68].
Neural agrin has up to 1000-fold greater AChR clustering activity
compared to other isoforms and was used throughout this study.
However the primary sequences between neural and muscle agrin
mainly differ at the Z insert, only 8 amino acids [69]. Considering
the large size of agrin, it is likely that the agrin autoantibodies also
recognize muscle agrin. Whether the antibodies against muscle
agrin are pathogenic would also be interesting to explore.
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